caa a22 4500 465737463 CHVBK 20180323111758.0 cr unu---uuuuu 170327e19901201xx s 000 0 eng 10.1007/BF02247135 doi (NATIONALLICENCE)springer-10.1007/BF02247135 Behavioural effects of the nicotinic agonists N-(3-pyridylmethyl)pyrrolidine and isoarecolone in rats [Elektronische Daten] [C. Reavill, J. Waters, I. Stolerman, H. Garcha] The nicotinic agonists N-(3-pyridylmethyl)pyrrolidine (PMP) and isoarecolone have been compared with (−)-nicotine in three behavioural procedures and as inhibitors of [3H]-(−)-nicotine binding. Locomotor activity was recorded as movements between beams of infra-red light (ambulation). In experimentally naive rats, nicotine, PMP and isoarecolone reduced ambulation. In rats receiving nicotine chronically and previously exposed to the activity cages, nicotine and PMP increased ambulation in a dose-related manner. However, isoarecolone did not increase ambulation at doses that were active in other procedures. In rats trained to discriminate nicotine from saline in a two-bar operant conditioning procedure with food reinforcement, there was full generalization to PMP. It was also found that PMP potently inhibited the binding of [3H]-(−)-nicotine to rat brain membranes in vitro. These results were discussed with previous data for the discriminative stimulus and ligand-binding effects of isoarecolone obtained under similar conditions. The relative potency of PMP in different behavioural procedures was similar to that of (−)-nicotine. However, isoarecolone was relatively 10 times more potent in decreasing ambulation than would have been expected from its potency in the ligand-binding and discriminative stimulus procedures. The results suggest that the pharmacodynamic action of isoarecolone differs from that of nicotine and PMP, and that it will be a useful probe in further analyses of central nicotinic mechanisms. Springer-Verlag, 1990 Nicotine nationallicence N-(3-pyridylmethyl)pyrrolidine nationallicence Isoarecolone nationallicence Nicotinic receptors nationallicence Locomotor activity nationallicence Drug discrimination nationallicence Reavill C. Department of Psychiatry, Institute of Psychiatry, De Crespigny Park, SE5 8AF, London, UK aut Waters J. Laboratory of Bioorganic Chemistry, NIDDK, National Institutes of Health, 20205, Bethesda, MD, USA aut Stolerman I. Department of Psychiatry, Institute of Psychiatry, De Crespigny Park, SE5 8AF, London, UK aut Garcha H. Department of Psychiatry, Institute of Psychiatry, De Crespigny Park, SE5 8AF, London, UK aut Psychopharmacology Springer-Verlag 102/4(1990-12-01), 521-528 0033-3158 102:4<521 1990 102 213 https://doi.org/10.1007/BF02247135 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF02247135 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Reavill C. Department of Psychiatry, Institute of Psychiatry, De Crespigny Park, SE5 8AF, London, UK aut NATIONALLICENCE 700 1- Waters J. Laboratory of Bioorganic Chemistry, NIDDK, National Institutes of Health, 20205, Bethesda, MD, USA aut NATIONALLICENCE 700 1- Stolerman I. Department of Psychiatry, Institute of Psychiatry, De Crespigny Park, SE5 8AF, London, UK aut NATIONALLICENCE 700 1- Garcha H. Department of Psychiatry, Institute of Psychiatry, De Crespigny Park, SE5 8AF, London, UK aut NATIONALLICENCE 773 0- Psychopharmacology Springer-Verlag 102/4(1990-12-01), 521-528 0033-3158 102:4<521 1990 102 213 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer